

Base Cost Apportionment
Demerger of Reckitt Benckiser Group plc's pharmaceuticals business

This information is provided as indicative guidance only. RB accepts no responsibility for the use that may be made of this information. Any individual wishing to calculate their Capital Gains Tax should consult an appropriate professional adviser.

The proposed demerger of Reckitt Benckiser Group plc's ("RB") global pharmaceuticals business was approved by RB's shareholders on 11 December 2014 and completed with the admission of Indivior PLC ("Indivior") to the London Stock Exchange at 8 a.m. on 23 December 2014. Shareholders registered on the RB share register at the Demerger Record Time of 6 p.m. on 22 December 2014 received one Indivior ordinary share for each RB ordinary share held.

For the purposes of taxation of chargeable gains, the base cost of RB shares held immediately before the demerger is apportioned between RB and Indivior shares as follows:

RB:	97.514%
Indivior:	2.486%

The apportionment, as prescribed by s.130(2) Taxation of Chargeable Gains Act 1992 ("TCGA"), is by reference to both companies' respective market values on 23 December 2014. Using the valuation methodology prescribed by s.272(3) TCGA, the market values of RB and Indivior shares were as follows:

RB:	£51.975
Indivior:	£1.325
